Published on 24 April 2013
Biosimilar development and regulation in Japan
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2013.0204.055
17.166 views
Published on 24 April 2013
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2013.0204.055
17.166 views
Published on 27 July 2016
Author(s): Ayesha Babar, BPharm, MPhil, Babar Khan, BPharm, MPH, PhD, Brian Godman, BSc, PhD, Shahzad Hussain, BPharm, MPhil, Sidra Mahmood, PharmD, MSc, Tahir Aqeel, BPharm, MPhil
API (active pharmaceutical ingredient), Drugs Regulatory Authority, generics, ibuprofen, Pakistan
DOI: 10.5639/gabij.2016.0504.041
17.151 views
Published on 04 April 2018
Author(s): Professor Roy Jefferis, PhD, DSc, MRCP, FRCPath
allotypes, erythropoietin, human IgG, idiotypes, immunogenicity, polymorphisms, post-translational modifications, structural heterogeneity
DOI: 10.5639/gabij.2018.0702.013
17.084 views
Published on 09 February 2016
Author(s): Adjunct Professor Pekka Kurki, MD, PhD, Cristina Avendaño-Solá, MD, PhD, Elena Wolff-Holz, MD, Martina Weise, MD, Niklas Ekman, PhD, Professor Andrea Laslop, MD, Professor Ferdinand Breedveld, MD, PhD, Professor Fernando Gomollón, MD, PhD, Professor Lluís Puig, MD, PhD, Professor Tore Kristian Kvien, MD, Robin Thorpe, PhD, FRCPath, Thijs J Giezen, PharmD, PhD, MSc, Vito Annese, MD
biologicals/biosimilars, extrapolation, interchangeability, medical societies, prescribers, regulators
DOI: 10.5639/gabij.2016.0502.019
16.877 views
Published on 02 July 2012
Author(s): Sabine MJM Straus, MD, PhD, Thijs J Giezen, PharmD, PhD, MSc
biologicals, biosimilars, immunogenicity, pharmacovigilance, traceability
DOI: 10.5639/gabij.2012.0103-4.033
16.846 views
Published on 02 September 2014
Author(s): European Biopharmaceutical Enterprises
biosimilars, EMA (European Medicines Agency), labels, PIL (product information leaflet), Summary of Product Characteristics (SmPC)
DOI: 10.5639/gabij.2014.0304.043
16.810 views
Published on 05 August 2013
Author(s): Gianluigi Casadei, MD
AIFA, biosimilars, market access, position paper, pricing, reimbursement
DOI: 10.5639/gabij.2013.0203.033
16.612 views
Published on 16 June 2014
Author(s): Alexander E Finlayson, MD, MRCP, Brian Godman, BSc, PhD, Houmei Xi, B Eng, Rickard E Malmstrom, MD, PhD, Wenjie Zeng, BSc, PhD
China, drug utilization study, generics, health policies, pharmaceuticals, statins
DOI: 10.5639/gabij.2014.0303.030
16.500 views
Published on 18 November 2013
Author(s): Pieter Dylst, PharmD, Professor Arnold G Vulto, PharmD, PhD, FCP, Steven Simoens, MSc, PhD
demand-side policies, Europe, European policy, generic medicines, supply-side policies
DOI: 10.5639/gabij.2014.0301.011
16.473 views
Published on 06 August 2013
Author(s): Janet S Wyatt, RN, PhD, FAANP
biological therapy, patient engagement, pharmacovigilance, treatment response
DOI: 10.5639/gabij.2014.0301.008
16.443 views
Published on 03 August 2020
ABP 215, administration, bevacizumab, biosimilar, infusion, stability
DOI: 10.5639/gabij.2020.0904.026
16.283 views
Published on 10 July 2018
Author(s): A Esquivel-Aguilar, PhD, CM Hernández-Guadarrama, MD, E Terreros-Muñoz, MD, G Castañeda-Hernández, JE García Ortiz, PhD, JI Navarrete-Martínez, MD, L Carbajal-Rodríguez, MD, M Cerón-Rodríguez, MD, Professor LC Correa-González, MD, SJ Franco-Ornelas, MD, Y Santillán-Hernández
biosimilar, Gaucher disease, imiglucerase, non-originator imiglucerase, orphan drugs
DOI: 10.5639/gabij.2019.0802.008
16.240 views